212 related articles for article (PubMed ID: 31635767)
1. Squamous Cell Carcinoma: PET/CT and PET/MRI of the Pretreatment and Post-Treatment Neck.
Traylor KS; Koontz N; Mosier K
Semin Ultrasound CT MR; 2019 Oct; 40(5):400-413. PubMed ID: 31635767
[TBL] [Abstract][Full Text] [Related]
2. Multimodal imaging analysis of an orthotopic head and neck cancer mouse model and application of anti-CD137 tumor immune therapy.
Vahle AK; Hermann S; Schäfers M; Wildner M; Kerem A; Öztürk E; Jure-Kunkel M; Franklin C; Lang S; Brandau S
Head Neck; 2016 Apr; 38(4):542-9. PubMed ID: 25482887
[TBL] [Abstract][Full Text] [Related]
3. Improving the accuracy of target volume delineation by combined use of computed tomography, magnetic resonance imaging and positron emission tomography in head and neck carcinomas.
Chauhan D; Rawat S; Sharma MK; Ahlawat P; Pal M; Gupta G; Dewan A; Gupta M; Sharma S; Dodagoudar C; Pahuja A; Mitra S; Sharma SK
J Cancer Res Ther; 2015; 11(4):746-51. PubMed ID: 26881512
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of
Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
[TBL] [Abstract][Full Text] [Related]
5. PET/MRI vs PET/CT in Head and Neck Imaging: When, Why, and How?
Ryan JL; Aaron VD; Sims JB
Semin Ultrasound CT MR; 2019 Oct; 40(5):376-390. PubMed ID: 31635765
[TBL] [Abstract][Full Text] [Related]
6. (18)F-Fluorodeoxyglucose PET/MR Imaging in Head and Neck Cancer.
Platzek I
PET Clin; 2016 Oct; 11(4):375-86. PubMed ID: 27593244
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and Limitations of FDG PET/CT for Imaging of Squamous Cell Carcinoma of the Head and Neck: A Comprehensive Review of Anatomy, Metastatic Pathways, and Image Findings.
Plaxton NA; Brandon DC; Corey AS; Harrison CE; Karagulle Kendi AT; Halkar RK; Barron BJ
AJR Am J Roentgenol; 2015 Nov; 205(5):W519-31. PubMed ID: 26496574
[TBL] [Abstract][Full Text] [Related]
8. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
9. Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma.
Mak D; Corry J; Lau E; Rischin D; Hicks RJ
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):487-99. PubMed ID: 22019706
[TBL] [Abstract][Full Text] [Related]
10. Influence of FDG-PET on primary nodal target volume definition for head and neck carcinomas.
van Egmond SL; Piscaer V; Janssen LM; Stegeman I; Hobbelink MG; Grolman W; Terhaard CH
Acta Oncol; 2016; 55(9-10):1099-1106. PubMed ID: 27219720
[TBL] [Abstract][Full Text] [Related]
11. Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI.
Schaarschmidt BM; Heusch P; Buchbender C; Ruhlmann M; Bergmann C; Ruhlmann V; Schlamann M; Antoch G; Forsting M; Wetter A
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):92-102. PubMed ID: 26243264
[TBL] [Abstract][Full Text] [Related]
12. Is there an additive value of 18 F-FDG PET-CT to CT/MRI for detecting nodal metastasis in oropharyngeal squamous cell carcinoma patients with palpably negative neck?
Sohn B; Koh YW; Kang WJ; Lee JH; Shin NY; Kim J
Acta Radiol; 2016 Nov; 57(11):1352-1359. PubMed ID: 26013025
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and
Ng SH; Liao CT; Lin CY; Chan SC; Lin YC; Yen TC; Chang JT; Ko SF; Fan KH; Wang HM; Yang LY; Wang JJ
Eur Radiol; 2016 Nov; 26(11):4162-4172. PubMed ID: 26911889
[TBL] [Abstract][Full Text] [Related]
14. PET/CT and PET/MRI in head and neck malignancy.
Szyszko TA; Cook GJR
Clin Radiol; 2018 Jan; 73(1):60-69. PubMed ID: 29029767
[TBL] [Abstract][Full Text] [Related]
15. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
Menda Y; Graham MM
Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
[TBL] [Abstract][Full Text] [Related]
16. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
17. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.
Nayak JV; Walvekar RR; Andrade RS; Daamen N; Lai SY; Argiris A; Smith RP; Heron DE; Ferris RL; Johnson JT; Branstetter BF
Laryngoscope; 2007 Dec; 117(12):2129-34. PubMed ID: 17921898
[TBL] [Abstract][Full Text] [Related]
18. Effect of 18F-fluorodeoxyglucose positron emission tomography on the management of patients with head and neck squamous cell carcinoma.
Goyal P; Hsu JM; Kellman RM
J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):694-9. PubMed ID: 19128678
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
[TBL] [Abstract][Full Text] [Related]
20. Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?
Castaldi P; Rufini V; Bussu F; Miccichè F; Dinapoli N; Autorino R; Lago M; De Corso E; Almadori G; Galli J; Paludetti G; Giordano A; Valentini V
Radiother Oncol; 2012 Apr; 103(1):63-8. PubMed ID: 22459579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
